{rfName}
An

Indexed in

Citations

11

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Feliu JAuthor

Share

January 21, 2025
Publications
>
Article
No

An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.

Publicated to: Clinical Cancer Research. - 2025-01-17 (), DOI: 10.1158/1078-0432.ccr-24-1934

Authors:

Xu C; Mannucci A; Esposito F; Oliveres H; Alonso Orduña V; Yubero A; Fernández-Martos C; Salud A; Gallego J; Martin-Richard M; Fernández-Plana J; Guillot M; Aparicio J; Fakih M; Kopetz S; Feliu J; Maurel J; Goel A
[+]

Affiliations

City Of Hope National Medical Center, Monrovia, CA, United States. - Author
City of Hope, Duarte, CA, United States. - Author
First Affiliated Hospital of Dalian Medical University, dalian, Liaoning, China. - Author
Hospital Clinic de Barcelona, Barcelona, Spain. - Author
Hospital General Universitario de Elche, Elche, Alicante, Spain. - Author
Hospital Quiron Salud, Valencia, Valencia, South Africa. - Author
Hospital Universitario La Paz. CIBERONC. IdiPAZ. Cátedra UAM-AMGEN, Madrid, Spain. - Author
Hospital Universitario Lozano Blesa, Spain. - Author
Hospital Universitario Miguel Servet, Zaragoza, Spain. - Author
Hospital Universitario Son Espases, Mallorca, Balearic Island, Spain. - Author
La Fe University Hospital, Valencia, Spain. - Author
University hospital Arnau de Vilanova of Lleida, Lleida, Lleida, Spain. - Author
University Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain. - Author
University of Barcelona, Barcelona, Cataluña, Spain. - Author
University of Barcelona, Barcelona, Spain. - Author
University of Texas MD Anderson Cancer Center, Houston, TX, United States. - Author
See more

Abstract

PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, and validate a liquid biopsy predictive of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- and left-sided, were enrolled in 2-nationwide trials to receive cetuximab or panitumumab along with chemotherapy. The primary endpoint was 12-month PFS, which was hierarchically tested in left- and right-sided mCRC to predict PFS, OS, and ORR. RESULTS Genome-wide small-RNA sequencing identified 12 cell-free and 14 exosomal candidates that were differentially expressed in both plasma and tumor tissue of good vs. poor responders (based on PFS <12 months). The 8 and 9 best-performing candidates, respectively, were used to generate the EXONERATE assay. In left-sided mCRC, 65% were EXONERATE-high, correlating with shorter mPFS (9.5 vs. 18.5 months, p<0.001). In the independent right-sided mCRC cohort, 80.8% were EXONERATE-high and experienced a similarly shorter mPFS (8.6 vs. 41.2 months, p=0.0004). In the right-sided group, EXONERATE predicted PFS≥12 months with 100% sensitivity. A linear relationship existed between EXONERATE values and response depth. Multivariate analysis revealed that EXONERATE predicts PFS and OS independently of tumor-sidedness. CONCLUSION The EXONERATE assay robustly predicted PFS and OS outcomes in patients with mCRC, both right- and left-sided, before they received either panitumumab or cetuximab. It stratified PFS, OS, and ORR better than a right vs. left approach.
[+]

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Cancer Research due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 29/328, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-07:

  • Open Alex: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-07:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 12.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 12 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 66.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 5 (Altmetric).
  • The number of mentions in news outlets: 8 (Altmetric).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 1 - End poverty in all its forms everywhere, with a probability of 64% according to the mBERT algorithm developed by Aurora University.
[+]